What CagriSema is
CagriSema is Novo Nordisk’s combination of cagrilintide, an amylin analogue, with semaglutide, the GLP-1 drug in Wegovy and Ozempic. Pairing the two targets is meant to produce more weight loss than semaglutide alone. Its Phase 3 REDEFINE program is complete and Novo submitted it to the FDA in December 2025, but it is not yet approved or available.
Mechanically, CagriSema is a once-weekly fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist).
What the trials show
In REDEFINE 1 (published in the New England Journal of Medicine in June 2025), CagriSema produced 22.7% average weight loss at 68 weeks on the full-adherence analysis, or 20.4% on the more conservative treatment-policy analysis, versus about 2.3% on placebo. In people with type 2 diabetes (REDEFINE 2) it was about 13.7–15.7%.
Can you get CagriSema yet?
CagriSema is not available yet. Novo filed it with the FDA in December 2025 and a decision is expected around the fourth quarter of 2026; there is no confirmed approval date, price, or coverage. Until the FDA acts, it cannot be prescribed in the US; cagrilintide is not an FDA-approved active ingredient, so a compounded version of it is not a legitimate route either.
The honest headline: CagriSema works, but it fell short of expectations. Management had signaled roughly 25% weight loss and the trial delivered 22.7%, and only about 57% of patients reached the top dose — Novo’s stock dropped sharply on the readout. It is effective but was a disappointment against its own target, and it is not available.
The options you can actually get now
While CagriSema moves through trials, the FDA-approved GLP-1 medicines are available today. If weight loss is the goal, see our comparison of the best approved GLP-1 options, the semaglutide and tirzepatide hubs, and the full list of GLP-1 medications.